期刊
FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.774414
关键词
renal fibrosis; Chinese herbs; monomers; chronic kidney disease; Abelmoschus manihot; Salvia miltiorrhiza; therapeutic molecular mechanism
资金
- National Natural Science Foundation of China [2020-81973807, 81670623, 81830021]
- State Outstanding Talents of Traditional Chinese Medicine Project of National Administration of Traditional Chinese Medicine [NATCM:2017-124]
- National key R&D Program of China [2018YFA0108802]
- US National Institutes of Health [2R01DK08506505A1]
The clinical and experimental study of Chinese herbal medicines on chronic kidney disease has made progress over the past 40 years, with five traditional Chinese herbs showing evidence of clinical efficacy and well-studied mechanisms.
The clinical and experimental study into the effects of Chinese herbal medicines on chronic kidney disease has evolved over the past 40 years with new insight into their mechanism and evidence of their clinical effects. Among the many traditional Chinese herbs examined in chronic renal disease, five were found to have evidence of sufficient clinical efficacy, high frequency of use, and well-studied mechanism. They are: Abelmoschus manihot and Huangkui capsule, Salvia miltiorrhiza and its components (tanshinone II A, salvianolic acid A and B); Rhizoma coptidis and its monomer berberine; Tripterygium wilfordii and its components (triptolide, tripterygium glycosides); Kudzu root Pueraria and its monomer Puerarin. These Chinese herbal medications have pharmaceutical effects against fibrosis, inflammation and oxidative stress and also promote renal repair and regeneration. This article reviews their clinical efficacy, anti-fibrotic effects in animal models, and molecular mechanism of action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据